#USA #Calgary #Innocan Pharma #BI Sky Global #HRIPT Testing

Innocan Pharma Achieves Significant Milestones

Innocan Pharma Corporation, a leader in the pharmaceutical and biotechnology sectors, has recently announced impressive accomplishments by its subsidiary, BI Sky Global. The company successfully completed the Human Repeated Insult Patch Test (HRIPT), a critical safety assessment for cosmetic products, and surpassed a superb sales milestone of 5,000 units sold daily during 2024.

HRIPT Testing Completion

The successful completion of HRIPT is a significant milestone for BI Sky Global, as it is the standard safety test for the personal care industry. This test assesses sensitization and irritation, ensuring that the products released into the market are safe for consumers. The successful outcome of HRIPT reflects the company’s rigorous quality assurance processes, aligning with its commitment to delivering safe and effective products.

Roni Kamhi, the CEO of BI Sky Global, commented on this achievement, highlighting that it showcases their dedication to high-quality standards. He stated, "Successfully completing the HRIPT testing and achieving a sales milestone of 5,000 units per day on average underscores our strong commitment to providing the highest quality products that are in demand by the market." This accomplishment sets BI Sky Global on a path to expand its sales and marketing efforts further, capitalizing on its market success.

Sales Milestone Achievement

In addition to the HRIPT completion, the company celebrated surpassing an average of 5,000 units sold daily in 2024. This milestone is particularly noteworthy since the typical minimum production for most cosmetic products is around 5,000 units. By achieving this daily sales volume, BI Sky Global not only meets but far exceeds the expectations for annual production agreements with major manufacturing partners.

Iris Bincovich, CEO of Innocan Pharma, expressed her enthusiasm about BI Sky Global’s performance, stating, "This is further clear evidence of how the strength of our subsidiary BI Sky Global's operations is delivering great value to our shareholders." The remarkable sales figures indicate a strong consumer demand for their cosmetic products and place the company in a favorable position for future growth.

About Innocan Pharma

Innocan Pharma Corporation is an innovator in the pharmaceuticals and wellness sectors. The company has developed a Cbd-loaded liposome drug delivery platform that provides precise dosage and controlled release of synthetic CBD for pain management. In addition to this, Innocan also focuses on a variety of high-performance self-care and beauty products designed to promote healthier lifestyles, marketed through its 60% owned subsidiary, BI Sky Global Ltd.

As Innocan Pharma continues to expand its product offerings and enhance its operational capabilities, the company is poised for continued success in an increasingly competitive market. The achievements of BI Sky Global, illustrated through both the HRIPT testing and substantial sales milestone, signal a promising future for Innocan Pharma and its stakeholders.

For more information on Innocan Pharma and their innovative products, visit www.innocanpharma.com.